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Which is the IDEAL Peginterferon for Hepatitis C: A Meta-Analysis of 
both Pegylated Interferons in the Treatment of HCV-Infected Patients
Frank Tacke
Department of Medicine III, RWTH-University Hospital Aachen, Aachen, Germany
Dear Editor,
C
hronic infections with the hepatitis C virus 
(HCV)  represent  a  major  global  health 
problem, with around 170 million patients at risk 
of  developing  life-threatening  complications  such 
as liver cirrhosis or hepatocellular carcinoma. The 
standard  treatment  of  care  is  a  combination  of 
weekly pegylated interferon (peginterferon) alfa and 
daily ribavirin for 24-72 weeks, dependent on HCV 
genotype  and  the  patient’s  individual  virological 
response to therapy (1, 2). Currently, there are two 
forms of peginterferon licensed for the treatment of 
hepatitis C: peginterferon alfa-2a (Pegasys, Roche) and 
peginterferon alfa-2b (Pegintron, Schering-Plough). 
Although  direct  pharmacodynamic  comparisons 
of  both  substances  have  shown  that  they  differ 
considerably with respect to pharmocokinetics and 
initial virological suppression (3), it remained largely 
unclear whether this is relevant for clinical endpoints, 
especially for achieving sustained virological response 
in HCV-infected patients.
In fact, the largest phase-3 trials for peginterferon 
alfa-2a and alfa-2b initially yielded somewhat similar 
outcomes (4, 5), establishing a “gut feeling” among 
many hepatologists worldwide that both substances 
were very likely equally potent in clinical practice. 
This was strongly supported by the largest endpoint 
trial to directly compare these two peginterferons, the 
IDEAL trial. In this trial, more than 3,000 patients 
were  randomized  to  receive  either  peginterferon 
alfa-2b (at two different doses, i.e. 1.0 or 1.5 µg/kg 
per week) or alfa-2a (at 180 µg/week), and similar 
sustained  virological  response  (SVR)  rates  were 
reported  for  all  three  treatment  groups  (6).  Two 
smaller recent studies reported by Rumi and Ascione 
this year (7, 8) challenged this conclusion by revealing 
a modest but significant increase in SVR for patients 
treated with peginterferon alfa-2a (Table 1). 
However,  findings  from  single  trials,  especially 
when  yielding  contradictory  results,  are  rarely 
definitive. It is therefore important to conduct a meta-
analysis of the available high-quality studies. Prof. 
Alavian and colleagues present in this issue of Hepatitis 
Monthly a thorough, up-to-date, and extensive meta-
analysis of studies comparing the efficacy of the two 
peginterferons  in  patients  chronically  infected  by 
HCV (9). This meta-analysis included 3,518 patients 
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